Analyst Josh Jennings of TD Cowen reiterated a Buy rating on Alphatec Holdings, with a price target of $22.50.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Josh Jennings’s rating is based on Alphatec Holdings’ impressive financial performance and strategic advancements. The company reported a remarkable 27% revenue growth in the second quarter of 2025, with surgical revenue increasing by 29%, significantly outpacing the spine market growth rate. This robust performance is complemented by a record adjusted EBITDA of $23 million, indicating a positive profitability trajectory.
Furthermore, Alphatec’s commitment to innovation is evident with the upcoming launch of the Valence robotic system in 2026. The company’s focus on procedural innovation and clinical distinction, particularly in the lateral segment with PTP and LTP offerings, has also led to a 21% increase in new surgeon adoption. These factors collectively suggest a strong future outlook, justifying the Buy rating.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATEC in relation to earlier this year.